- Bernstein DI, Harrison CJ, Effects of the immunomodulating agent R-837 on acute and latent herpes simplex virus type 2 infections. Antimicrob Agents Chemother (1989) 33: 1511-15.
- Harrison CJ, Miller RL, Bernstein DI, Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in Guinea pigs. Antimicrob Agents Chemother (1994) 38: 2059-64.
- Richwald GA, Imiquimod. Drugs of Today (1999) 35(7): 497-511.
- Beutner KR, Spruance SL, Hougham AJ et al, Treatment of genital warts with an immune-response modifier (imiquimod).J Am Acad Drematol (1998) 38: 230-9.
- Suzuki H, Wang B, Amerio P et al, Imiquimod, a novel immune response modifier induces migration of Langerhans cells. J Invest Dermatol (2000) 114: 135-41.
- Tygum KI, Smith SL, Myers JA et al, Percutaneous penetration of [14C] Imiquimod from a single application of cream. Pharm Res (1995) 12(9): s277.
- Edwards L, Ferenczy A, Eron L et al, Self-administered topical 5% Imiquimod cream for external anogenital warts. Arch Dermatol ( 1998) 134: 25-30.
- Mayers DL, New treatments for genital warts less than ideal. JAMA (1998) 279: 2002-3.
- Langley PC, Tyring SK, Smith MH et al, The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Managed Care (I999) 5(1): 69-77.
- 55th edition (2001) Physicians desk reference. Medical Economic Company Inc. Montvale. NJ.
- Syed SA, Goswami J, Ahmadpour OA et al, Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled double-blind study. J Dermatol (1998) 25: 309-13.
- Buckley R, Smith K, Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease. Arch Dermatol (1999) 135: 1167-9.
- Dubin N, Kopf AW, Multivariate risk score for recurrence of cutaneous basal cell carcinomas. Arch Dermatol (1983) 119: 373-7.
- Beutner KR, Geisse JK, Helman D et al, Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol (1999) 41: 1002-7.
- Mackenzie-Wood A de Launey J, Kossard S et al, Safety and efficacy of imiquimod 5% cream for the treatment of Bowen' s disease. J Invest Dermatol (1998) 110:684.
- Wagner TL, Ahonen CL, Couture AM et al, Modulation of THl and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol (1999) 191: 10-19.
- Beutner KR, Reitano MV, Richwald GA et al, External genital warts: report of the American Medical Association consensus conference. Clin Infect Dis (1998) 27: 796-806.
- Beutner KR, Tyring SK, Trofatter KF et al, Imiquimod, a patient-applied immune response modifier for treatment of external genital warts. Antimicrob Agents Chemother (1998) 42: 789-94.
Journal of Dermatological Treatment
Volume 12, 2001 - Issue 1